A Real-world, Prospective Observational Study of Rimegepant ODT for the Acute Treatment of Migraine Attacks in Adults.
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →. With Aptar Digital Health.
Phase
—
Status
Completed
Study type
Observational
Enrollment
467actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-02 | actual | When the study began enrolling |
| Primary completion | 2025-03-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-11 | actual | The whole study's end, after follow-up |
| First posted | 2024-06-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Migraine
Primary outcomes
what the primary-completion date above is the date OFSatisfaction with prescribed medication
measured Day 30
Population level consistency
measured Day 30
Assessments of meaningful clinical effect
measured Day 30
meaningful improvement in functioning
measured Day 30
Publications
- PMID 42286469 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed